OSE Immunotherapeutics SA announced the appointment of Iris Pauporté as Clinical Project Director to reinforce the team’s scientific expertise. Iris will be leading the international registration Phase 3 clinical trial with Tedopi®, an innovative combination of neoepitopes developed in immuno-oncology in advanced lung cancer (NSCLC). She will also be involved in the preparation of a Phase 2 clinical trial considered in 2017 with Tedopi® combined with a checkpoint inhibitor, and in exploring Tedopi® in other cancer indications. Iris Pauporté has more than 20 years’ experience in biomedical and clinical research, both in the pharmaceutical industry and at the French National Cancer Institute.